PeterMD and Lorient Partner to Accelerate Growth of the Nation’s First Fully Integrated Medicine 3.0 Platform

▤ Summary

PeterMD announced a majority equity investment from Lorient, alongside Emanate, to accelerate national expansion of its Medicine 3.0 telehealth platform. The funding will scale PeterMD’s integrated digital offering that combines advanced diagnostics, 60+ biomarker lab panels, personalized hormone, weight-loss and peptide treatments, and continuous primary care. David Prokupek joins PeterMD’s board as Executive Chair to support scaling and consumer-wellness growth. Lorient says it selected PeterMD after thematic research and plans to deploy its operational L1OS and data platform to drive measurable performance across the business.

$ Funding

▦ Linked Companies